SUNPHARMA

Technical View- Technical View (As of Latest Chart on 05-08-2025):

SUNPHARMA Stock has broken down from higher levels (1730+ to 1620). RSI is near 40 (weak zone), MACD in deep negative. Trend reversal signs not yet visible. Support around ₹1600; if breaks, ₹1540-1500 zone may come. Why Is SUNPHARMA Sun Pharma Falling? 1-Earnings Disappointment 2-Regulatory Headwinds 3-Global Trade Tensions 4-Weak Analyst Sentiment & Guidance 5-Sectoral Weakness 6-Specialty Portfolio Under Pressure What to do BUY, SELL & HOLD? For long-term investors, Sun Pharma remains a fundamentally strong company, and gradual accumulation during dips (₹1500–₹1550 zone) may be considered using a SIP approach. The focus should remain on its core strengths, such as R&D, global presence, and a strong balance sheet. However, short-term traders are advised to stay cautious and avoid entering prematurely, as the stock is under technical pressure. A clear reversal with strong volume and price action is necessary before considering fresh positions for short-term trades. Let the trend confirm before taking action. Positive Points (Long-Term View): India's Largest Pharma Company – Diversified portfolio across generics, branded generics, and specialty. Strong Presence in US & Emerging Markets – US remains a key market, despite recent concerns. Specialty Drug Focus – Long-term growth driver. Debt-Free or Low Leverage – Strong balance sheet and cash flows. R&D Strength – Continuous investment in research. Current Challenges (Short-Term View): USFDA Halol Plant Issues – Regulatory risk (8 observations recently). Profit Miss in Q1 FY26 – Net profit down ~20% YoY, despite revenue growth. SPARC Drug Trial Failure – Negative for long-term innovation outlook. Global Pharma Pressure – US tariffs news created short-term volatility. Technical Weakness – Stock broke support levels, bearish momentum on chart.